Checking Our Nation’s Pulse- Heart Rhythm 2021!

More than 14 million Americans currently live with heart rhythm disorders, with approximately 160,000 new atrial fibrillation cases, the most common type of cardiac arrhythmia, being diagnosed every year. Currently, atrial fibrillation accounts for approximately one-third of hospitalizations for cardiac rhythm disturbances in the U.S. and increases the risk of stroke fivefold1. As the population in the U.S. and the world ages, it is expected that almost six million adults will be diagnosed with atrial fibrillation over the next 40 years2.

In 1979, in response to this growing health crisis, four electrophysiologists met in Boston to discuss the ever-increasing arrhythmia epidemic and the need for a platform for experts to collaborate on critical fields of electrophysiology and cardiac management. In one of the healthcare capitals of the world, Doctor’s J Warren Harthorne, Victor Parsonnet, Seymour Furman, and Dryden Morse gave birth to the Heart Rhythm Society3.

Today, 42 years later, the HRS is recognized as the premier non-profit organization dedicated to ending the widespread health effects and suffering caused by heart rhythm disorders. With over 5800 members across 70 countries, HRS is a leading resource for electrophysiology and heart rhythm disorders that provides access to leading-edge science, research, and innovation. Physicians, patients, and allied health professionals have benefited from the resources, support, and advocacy afforded by the HRS (see, for example, the Heart Rhythm Journal), premier education courses in cardiac electrophysiology, comprehensive awareness initiatives, patient resources, and sponsored and co-sponsored events).

While the organization has expanded both internationally and in size, HRS has never lost sight of its local roots or its steadfast mission of unifying the field of cardiovascular care. Every July, the Society invites industry and academic leaders to convene for a three-day conference in the birthplace of its society—Boston, MA—to share and explore the advancements in cardiac rhythm management and electrophysiology.

The Heart Rhythm 2021 Annual Convention is a benchmark event for HRS and its devoted peers. BioSig is thrilled to be presenting during the convention for the third consecutive year. From July 28th to the 30th, BioSig will be hosting a calendar of events designed to showcase our revolutionary PURE EP™ System. Whether you are a physician, industry professional, patient, investor, or a medical student aspiring to join the field of electrophysiology, we encourage you to visit booth #849 at the Boston Convention Center to learn about the PURE EP™’s innovative science and revolutionary potential from the experts that developed the system and the physicians that use it to in their daily practice.

BioSig’s HRS2021 Program Highlights:

Evening Event 1: Wednesday, July 28, 6:30-9PM ET PURE EP™: A New Standard in Signal Processing

Evening Event 2: Thursday, July 29, 5:30-8PM ET: PURE EP™: Clinical Data to Clinical Applications

Scientific Presentation 1: Thursday, July 29, 9:30-9:40AM ET: Pedram Kazemian, MD: Post-ablation bipolar voltage by PURE EP™ as a marker of transmural lesion

Scientific Presentation 2: Thursday, July 29, 3:50-4:00PM ET: Jonathan Salas, B.S: Atrial unipolar electrogram filtering to better delineate amplitude and morphology during radiofrequency ablation

Reach out to us on if you would like to attend any of these events.

I am profoundly grateful to the HRS for hosting this event, and more importantly, for representing and advocating for this growing healthcare field. While a healthy heartbeat may be quiet, HRS has given voice to this critical cause. To support their efforts, click here to make a donation to HRS.

As a company, we strive to emulate the HRS’s mission each day. This year, I have never felt closer to our goal of setting a new standard in the treatment of cardiac arrhythmias. We look forward to sharing our latest clinical milestones and data with the rest of the EP world at HRS 2021 and hope to see you there!


Ken Londoner, CEO & Co-Founder,
BioSig Technologes, Inc.


Return to Listings